Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of JNJ-64140284 in Healthy Men
NCT04566926Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-64140284 in epilepsy, sponsored by Janssen Pharmaceutical. Primary endpoints: Plasma Concentration of JNJ-64140284 at Day 4, Urine Concentration of JNJ-64140284 at Day 4 and 2 more. Started Sep 2020; status: terminated.
02
Drugs
JNJ-64140284
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT04566926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04566926.